View all news

ANI Announces Appointment of Mark J. Ginski Ph.D as Vice President Corticotropin Product Development

05/23/2016


BAUDETTE, Minnesota (May 23, 2016) - ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced the appointment of Mark Ginski Ph.D as Vice President Corticotropin Product Development, effective May 23, 2016.


Mark J. Ginski is an accomplished scientist with over 20 years of experience in API and drug product development, formulation, analytical development and API and drug product manufacturing. Mark has held various positions in specialty drug development with Shire Pharmaceuticals, Alba Therapeutics, Cerecor Inc, Questcor Pharmaceuticals and most recently, Mallinckrodt Pharmaceuticals, where he was the Senior Director, CMC and Operations for Autoimmune and Rare Diseases.


Arthur S. Przybyl, ANI’s President and Chief Executive Officer stated, “I am pleased that Mark has joined ANI to help lead the advancement of our most exciting pipeline opportunity, the re-commercialization of our corticotrophin NDAs. I am confident that Mark’s diverse and highly relevant experience will bring valuable insights to this project. We intend to further expand ANI’s bench strength on this critical project and add additional subject matter experts in the near future.”


About ANI


ANI Pharmaceuticals, Inc. (the “Company” or “ANI”) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website anipharmaceuticals.com.


Forward-Looking Statements


To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects , the Company’s pipeline or potential markets therefor, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.


Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; increased competition; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.


More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com

Multimedia Files:

View all news